Related Experiment Video
Updated: Aug 12, 2025

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.2K
Intermittent Androgen Deprivation for Biochemically Recurrent Prostate Cancer: First Do No Harm
Anthony V Serritella1, Sarah E Fenton1, Maha Hussain1
1Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
European Urology Focus
|January 27, 2023
Abstract:
Intermittent androgen deprivation therapy in patients with prostate cancer and biochemical relapse does not prolong survival or improve quality of life.

